Healthcare
17 columns
100 rows
8 formats

Liquid Biopsy and Circulating Tumor DNA (ctDNA)

This dataset provides comprehensive records of liquid biopsy samples and circulating tumor DNA (ctDNA) analysis for cancer patients, including molecular findings, treatment details, and clinical outcomes. It enables longitudinal monitoring of minimal residual disease, treatment response, and resistance mutations, supporting research and clinical decision-making in precision oncology.

last updated 2 Nov 2025
by GoMask

The brief that made it

Longitudinal monitoring of cancer patients for minimal residual disease and treatment response

Sample rows

preview · 8 of 100 rows · all 17 columns

sample_idstring	treatment_responsestring	ctdna_levelfloat	resistance_mutation_detectedboolean	resistance_mutation_liststring	patient_idstring	collection_datedate	cancer_typestring	stagestring	minimal_residual_disease_detectedboolean	treatment_typestring	treatment_start_datedate	sequencing_methodstring	laboratory_namestring	report_datedate	clinician_idstring	notesstring
LB202401-001	partial response	3.52	false	blank	PAT1001	2024-01-05	lung	III	true	chemotherapy	2023-12-15	NGS	GenomicDx Labs	2024-01-06	CLN5001	Patient experienced mild nausea, MRD positive.
LB202401-002	stable disease	0	false	blank	PAT1002	2024-01-07	breast	II	false	immunotherapy	2023-11-20	digital PCR	Precision Oncology	2024-01-08	CLN5002	No MRD detected; patient remains stable.
LB202401-003	progressive disease	7.41	true	KRAS G12D, NRAS Q61K	PAT1003	2024-01-09	colorectal	IV	true	targeted therapy	2023-10-02	NGS	OncoSeq Diagnostics	2024-01-10	CLN5003	Resistance mutations detected; recommend regimen change.
LB202401-004	not evaluated	0	false	blank	PAT1004	2024-01-10	prostate	I	false	chemotherapy	2023-09-16	digital PCR	GenomicDx Labs	2024-01-11	CLN5004	First biopsy for baseline testing.
LB202401-005	partial response	2.14	false	blank	PAT1005	2024-01-12	lung	II	true	immunotherapy	2023-12-10	NGS	OncoSeq Diagnostics	2024-01-13	CLN5005	Low MRD detected, continue monitoring.
LB202401-006	stable disease	0	false	blank	PAT1002	2024-01-14	breast	II	false	immunotherapy	2023-11-20	digital PCR	Precision Oncology	2024-01-15	CLN5002	No ctDNA detected, patient stable.
LB202401-007	progressive disease	6.75	true	BRCA1 185delAG	PAT1006	2024-01-16	ovarian	III	true	chemotherapy	2023-12-03	NGS	GenomicDx Labs	2024-01-17	CLN5006	Progression noted, resistance mutation present.
LB202401-008	stable disease	8.88	true	EGFR T790M	PAT1007	2024-01-18	lung	IV	true	targeted therapy	2023-10-25	NGS	OncoSeq Diagnostics	2024-01-19	CLN5007	EGFR T790M detected; patient under review.
LB202401-009	complete response	0	false	blank	PAT1008	2024-01-20	colorectal	II	false	chemotherapy	2023-09-29	digital PCR	Precision Oncology	2024-01-21	CLN5008	Complete response, no MRD detected.
LB202401-010	not evaluated	0	false	blank	PAT1009	2024-01-22	breast	I	false	chemotherapy	2023-09-12	NGS	GenomicDx Labs	2024-01-23	CLN5009	No ctDNA detected; baseline sample.
LB202401-011	progressive disease	11.22	true	ALK L1196M	PAT1010	2024-01-24	lung	IV	true	targeted therapy	2023-09-01	digital PCR	OncoSeq Diagnostics	2024-01-25	CLN5010	ALK resistance mutation detected.
LB202401-012	stable disease	0	false	blank	PAT1011	2024-01-26	colorectal	III	false	chemotherapy	2023-09-08	NGS	GenomicDx Labs	2024-01-27	CLN5011	Stable disease, low ctDNA.
LB202401-013	partial response	2.98	false	blank	PAT1012	2024-01-28	breast	II	true	immunotherapy	2023-12-22	digital PCR	Precision Oncology	2024-01-29	CLN5012	MRD detected; continue close follow up.
LB202401-014	progressive disease	5.45	true	EGFR C797S	PAT1013	2024-01-30	lung	III	true	targeted therapy	2023-10-22	NGS	GenomicDx Labs	2024-01-31	CLN5013	EGFR resistance mutation detected; therapy adjustment needed.
LB202401-015	complete response	0	false	blank	PAT1014	2024-02-01	ovarian	II	false	chemotherapy	2023-11-15	digital PCR	Precision Oncology	2024-02-02	CLN5014	No MRD, patient achieved complete response.
LB202401-016	not evaluated	0	false	blank	PAT1015	2024-02-03	prostate	I	false	targeted therapy	2023-09-18	NGS	GenomicDx Labs	2024-02-04	CLN5015	Initial sample, no ctDNA detected.
LB202401-017	stable disease	9.36	false	blank	PAT1016	2024-02-05	lung	IV	true	chemotherapy	2023-12-10	digital PCR	OncoSeq Diagnostics	2024-02-06	CLN5016	MRD positive, monitor for progression.
LB202401-018	partial response	4.68	false	blank	PAT1017	2024-02-07	breast	III	true	immunotherapy	2023-12-29	NGS	GenomicDx Labs	2024-02-08	CLN5017	Partial response, ctDNA reduced.
LB202401-019	progressive disease	10.11	true	KRAS G13D, BRAF V600E	PAT1018	2024-02-09	colorectal	IV	true	targeted therapy	2023-10-03	digital PCR	OncoSeq Diagnostics	2024-02-10	CLN5018	Multiple resistance mutations found.
LB202401-020	stable disease	0	false	blank	PAT1019	2024-02-11	lung	II	false	chemotherapy	2023-09-21	NGS	GenomicDx Labs	2024-02-12	CLN5019	Stable disease, MRD not detected.

What the 100 rows show

from the 100-row sample

Progressive disease (treatment response) stands out: 27 of its 27 rows have resistance_mutation_detected = true, against 2 of 73 for the rest.

29%resistance_mutation_detected = true
4.0median ctdna_level
2sequencing methods
3treatment types
4stages
5cancer types

Resistance mutation detected rate by treatment_responseresistance_mutation_detected = true

ctdna_level100 rows, in bands of 5

Median 4.0, from 0.0 to 45.1.

resistance_mutation_list29 rows with a value · 71 left blank

EGFR T790M6
EGFR C797S3
EGFR L858R3
KRAS G12D3
KRAS G12C2
AR-V72
KRAS G12C,EGFR T790M2
EGFR T790M,KRAS G12C2
KRAS G12D, NRAS Q61K1
BRCA1 185delAG1

17 columns by typefrom the column list below

string 11
float 1
date 3
boolean 2

Columns

17 columns in four groups

blueprint · 17 columns
column	type	description	example
Text 11 columns
`sample_id`	string	Unique identifier for each liquid biopsy sampleunique	LB202401-001
`patient_id`	string	Unique identifier for the patient from whom the sample was collected	PAT1001
`cancer_type`	string	Type of cancer diagnosed in the patient (e.g., lung, breast, colorectal)5 types	lung
`stage`	string	Cancer stage at time of sample collection (e.g., I, II, III, IV)0 · I · II · III · IV · optional	III
`treatment_type`	string	Type of treatment patient is receiving at time of sample (e.g., chemotherapy, immunotherapy, targeted therapy)3 types · optional	chemotherapy
`treatment_response`	string	Clinical assessment of patient's response to treatment (e.g., partial response, stable disease, progressive disease)5 values · optional	partial response
`resistance_mutation_list`	string	Comma-separated list of resistance mutations detected (e.g., EGFR T790M, KRAS G12C)optional	KRAS G12D, NRAS Q61K
`sequencing_method`	string	Method used for ctDNA analysis (e.g., NGS, digital PCR)2 methods · optional	NGS
`laboratory_name`	string	Name of the laboratory performing the ctDNA test8 names · optional	GenomicDx Labs
`clinician_id`	string	Identifier for the clinician responsible for patient careoptional	CLN5001
`notes`	string	Additional comments or observations related to the sample or patientoptional	Low MRD detected.
Numbers 1 column
`ctdna_level`	float	Quantitative level of circulating tumor DNA detected (ng/mL)0 or more · optional	3.52
Dates and times 3 columns
`collection_date`	date	Date the liquid biopsy sample was collected	2024-01-05
`treatment_start_date`	date	Date the current treatment regimen startedoptional	2023-12-15
`report_date`	date	Date the ctDNA test report was issuedoptional	2024-01-06
True or false 2 columns
`minimal_residual_disease_detected`	boolean	Indicates if minimal residual disease (MRD) was detected in the sampleoptional	true
`resistance_mutation_detected`	boolean	Indicates if resistance mutations were detected in ctDNAoptional	false

Use it for

A healthcare dashboard
The resistance_mutation_detected rate, ctdna_level by treatment_response and a breakdown of resistance_mutation_list. Excel, Power BI or Tableau.
Why do 29 of 100 rows have resistance_mutation_detected = true?
A root-cause class exercise
Hand out the rows and one question. The answer is in the data, not in the brief.
Samples100
LB202401-0013.52partial …
LB202401-0037.41progress…
LB202401-0076.75progress…
A software demo
Believable samples with patient_id, collection_date and cancer_type to fill a screen in front of a buyer.

This dataset100 rows17 columns

Yours1,000 rows17 columns

blueprint · liquid-biopsy-and-circulating-tumor-dna-ctdna

Behind this dataset

Same schema. As many rows as you need.

These 100 rows came out of a blueprint — 17 columns with generation rules behind each one. Open it in Data Factory to retune a column, add your own, wire in foreign keys, and run it at the size you actually need.

Rules it was built with

Sample ID unique per blood draw
Sample type: plasma, serum
Timepoint: baseline, on-treatment, post-treatment, surveillance
ctDNA detected: yes or no
Variant allele fraction (VAF) in plasma
Somatic mutations detected matching tumor
Emerging resistance mutations (e.g., T790M in EGFR)
Minimal residual disease (MRD) monitoring post-surgery

Rows1,000 rows10,000 rows100,000 rows1,000,000 rows

Open the blueprint in Data Factory

1 credit per row. Preview 20 rows free. Buy rows for the full run.

Exports: CSV, JSON, JSONL, Parquet, SQL, Excel, TSV, XML
Licence: yours to use, including commercially
API slug: liquid-biopsy-and-circulating-tumor-dna-ctdna

What should your data show?

No signup. No card.

Sample rows

What the 100 rows show

Columns

Use it for

A healthcare dashboard

A root-cause class exercise

A software demo

Make it yours.

Same schema. As many rows as you need.

More in Healthcare

What should your data show?